{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T12:38:53Z","timestamp":1791722333567,"version":"4.3.4"},"reference-count":39,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thrombosisresearch.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Thrombosis Research"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.thromres.2025.109540","type":"journal-article","created":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T09:09:53Z","timestamp":1763629793000},"page":"109540","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Platelet Thromboxane B2 overproduction associated with liver fibrosis severity in patients with MASLD"],"prefix":"10.1016","volume":"257","author":[{"given":"Francesco","family":"Baratta","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas","family":"Cocomello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guido","family":"Carpino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Colantoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vittoria","family":"Cammisotto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simona","family":"Bartimoccia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Castellani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diletta","family":"Overi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierleone","family":"Lucatelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evaristo","family":"Ettorre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Carnevale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pasquale","family":"Pignatelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniele","family":"Pastori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Del Ben","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eugenio","family":"Gaudio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovambattista","family":"Desideri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Violi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.thromres.2025.109540_bb0005","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1016\/j.jhep.2023.06.003","article-title":"A multisociety Delphi consensus statement on new fatty liver disease nomenclature","volume":"79","author":"Rinella","year":"2023","journal-title":"J. Hepatol."},{"key":"10.1016\/j.thromres.2025.109540_bb0010","article-title":"Can we use old NAFLD data under the new MASLD definition?","author":"Song","year":"2023","journal-title":"J. Hepatol."},{"issue":"1","key":"10.1016\/j.thromres.2025.109540_bb0015","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1002\/hep.28431","article-title":"Global epidemiology of nonalcoholic fatty liver disease\u2014meta-analytic assessment of prevalence, incidence, and outcomes","volume":"64","author":"Younossi","year":"2016","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.thromres.2025.109540_bb0020","doi-asserted-by":"crossref","DOI":"10.1097\/HC9.0000000000000352","article-title":"The changing epidemiology of adult liver transplantation in the United States in 2013\u20132022: the dominance of metabolic dysfunction-associated steatotic liver disease and alcohol-associated liver disease","volume":"8","author":"Younossi","year":"2024","journal-title":"Hepatol. Commun."},{"issue":"14","key":"10.1016\/j.thromres.2025.109540_bb0025","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1056\/NEJMra0912063","article-title":"Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease","volume":"363","author":"Targher","year":"2010","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.thromres.2025.109540_bb0030","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1002\/hep.21327","article-title":"Long-term follow-up of patients with NAFLD and elevated liver enzymes","volume":"44","author":"Ekstedt","year":"2006","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.thromres.2025.109540_bb0035","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1053\/j.gastro.2005.04.014","article-title":"The natural history of nonalcoholic fatty liver disease: a population-based cohort study","volume":"129","author":"Adams","year":"2005","journal-title":"Gastroenterology"},{"issue":"Suppl. 3","key":"10.1016\/j.thromres.2025.109540_bb0040","doi-asserted-by":"crossref","first-page":"S291","DOI":"10.1007\/s11739-012-0819-4","article-title":"Non-alcoholic fatty liver disease and cardiovascular disease: epidemiological, clinical and pathophysiological evidences","volume":"7","author":"Del Ben","year":"2012","journal-title":"Intern. Emerg. Med."},{"issue":"11","key":"10.1016\/j.thromres.2025.109540_bb0045","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1016\/S2468-1253(21)00308-3","article-title":"Non-alcoholic fatty liver disease and risk of fatal and non-fatal cardiovascular events: an updated systematic review and meta-analysis","volume":"6","author":"Mantovani","year":"2021","journal-title":"Lancet Gastroenterol. Hepatol."},{"issue":"4","key":"10.1016\/j.thromres.2025.109540_bb0050","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1007\/s12072-023-10543-8","article-title":"An international multidisciplinary consensus statement on MAFLD and the risk of CVD","volume":"17","author":"Zhou","year":"2023","journal-title":"Hepatol. Int."},{"issue":"7329","key":"10.1016\/j.thromres.2025.109540_bb0055","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1136\/bmj.324.7329.71","article-title":"Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients","volume":"324","author":"Antithrombotic","year":"2002","journal-title":"Bmj"},{"issue":"7","key":"10.1016\/j.thromres.2025.109540_bb0060","doi-asserted-by":"crossref","first-page":"11B","DOI":"10.1016\/0002-9149(91)90379-Y","article-title":"Mechanisms of platelet activation: thromboxane A2 as an amplifying signal for other agonists","volume":"68","author":"FitzGerald","year":"1991","journal-title":"Am. J. Cardiol."},{"issue":"4","key":"10.1016\/j.thromres.2025.109540_bb0065","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1038\/s41591-019-0379-5","article-title":"Platelet GPIb\u03b1 is a mediator and potential interventional target for NASH and subsequent liver cancer","volume":"25","author":"Malehmir","year":"2019","journal-title":"Nat. Med."},{"key":"10.1016\/j.thromres.2025.109540_bb0070","article-title":"Increased liver localization of lipopolysaccharides in human and experimental non-alcoholic fatty liver disease","author":"Carpino","year":"2019","journal-title":"Hepatology"},{"issue":"13","key":"10.1016\/j.thromres.2025.109540_bb0075","doi-asserted-by":"crossref","first-page":"2776","DOI":"10.1016\/j.cgh.2019.04.061","article-title":"Daily aspirin use associated with reduced risk for fibrosis progression in patients with nonalcoholic fatty liver disease","volume":"17","author":"Simon","year":"2019","journal-title":"Clin. Gastroenterol. Hepatol."},{"issue":"1","key":"10.1016\/j.thromres.2025.109540_bb0080","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1186\/s12933-024-02263-6","article-title":"Lipid-based insulin-resistance markers predict cardiovascular events in metabolic dysfunction associated steatotic liver disease","volume":"23","author":"Colantoni","year":"2024","journal-title":"Cardiovasc. Diabetol."},{"issue":"6","key":"10.1016\/j.thromres.2025.109540_bb0085","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.1097\/HEP.0000000000000520","article-title":"A multisociety Delphi consensus statement on new fatty liver disease nomenclature","volume":"78","author":"Rinella","year":"2023","journal-title":"Hepatology"},{"key":"10.1016\/j.thromres.2025.109540_bb0090","doi-asserted-by":"crossref","DOI":"10.1038\/ctg.2015.43","article-title":"Similar reduction of cholesterol-adjusted vitamin E serum levels in simple steatosis and non-alcoholic steatohepatitis","volume":"6","author":"Pastori","year":"2015","journal-title":"Clin. Transl. Gastroenterol."},{"issue":"6","key":"10.1016\/j.thromres.2025.109540_bb0095","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1002\/hep.20701","article-title":"Design and validation of a histological scoring system for nonalcoholic fatty liver disease","volume":"41","author":"Kleiner","year":"2005","journal-title":"Hepatology"},{"issue":"3","key":"10.1016\/j.thromres.2025.109540_bb0100","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1002\/hep.24127","article-title":"Nonalcoholic fatty liver disease (NAFLD) activity score and the histopathologic diagnosis in NAFLD: distinct clinicopathologic meanings","volume":"53","author":"Brunt","year":"2011","journal-title":"Hepatology"},{"key":"10.1016\/j.thromres.2025.109540_bb0105","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.thromres.2018.01.010","article-title":"Influence of pre-analytical time and temperature conditions on serum thromboxane B","volume":"163","author":"van Diemen","year":"2018","journal-title":"Thromb. Res."},{"issue":"5","key":"10.1016\/j.thromres.2025.109540_bb0110","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1160\/TH16-05-0349","article-title":"Patient-independent variables affecting the assessment of aspirin responsiveness by serum thromboxane measurement","volume":"116","author":"Petrucci","year":"2016","journal-title":"Thromb. Haemost."},{"key":"10.1016\/j.thromres.2025.109540_bb0115","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.atherosclerosis.2018.04.025","article-title":"Blood hydrogen peroxide break-down activity in healthy subjects and in patients at risk of cardiovascular events","volume":"274","author":"Carnevale","year":"2018","journal-title":"Atherosclerosis"},{"issue":"16","key":"10.1016\/j.thromres.2025.109540_bb0120","doi-asserted-by":"crossref","first-page":"5861","DOI":"10.1073\/pnas.83.16.5861","article-title":"11-Dehydrothromboxane B2: a quantitative index of thromboxane A2 formation in the human circulation","volume":"83","author":"Catella","year":"1986","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"3","key":"10.1016\/j.thromres.2025.109540_bb0125","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/j.jhep.2024.04.031","article-title":"EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD)","volume":"81","author":"EAftSotL (EASL)","year":"2024","journal-title":"J. Hepatol."},{"issue":"4","key":"10.1016\/j.thromres.2025.109540_bb0130","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1055\/s-0037-1615058","article-title":"Increased thromboxane metabolites excretion in liver cirrhosis","volume":"79","author":"Dav\u00ec","year":"1998","journal-title":"Thromb. Haemost."},{"issue":"5","key":"10.1016\/j.thromres.2025.109540_bb0135","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1160\/TH15-03-0202","article-title":"Aspirin for primary prevention in diabetes mellitus: from the calculation of cardiovascular risk and risk\/benefit profile to personalised treatment","volume":"114","author":"Santilli","year":"2015","journal-title":"Thromb. Haemost."},{"issue":"2","key":"10.1016\/j.thromres.2025.109540_bb0140","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1160\/TH14-01-0094","article-title":"Statin therapy and thromboxane generation in patients with coronary artery disease treated with high-dose aspirin","volume":"112","author":"Bliden","year":"2014","journal-title":"Thromb. Haemost."},{"issue":"12","key":"10.1016\/j.thromres.2025.109540_bb0145","doi-asserted-by":"crossref","DOI":"10.3390\/jcm11123471","article-title":"Urine 11-dehydro-thromboxane B2 in aspirin-naive males with metabolic syndrome","volume":"11","author":"Piechota","year":"2022","journal-title":"J. Clin. Med."},{"issue":"13","key":"10.1016\/j.thromres.2025.109540_bb0150","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22137193","article-title":"Proprotein convertase subtilisin kexin type 9 inhibitors reduce platelet activation modulating ox-LDL pathways","volume":"22","author":"Cammisotto","year":"2021","journal-title":"Int. J. Mol. Sci."},{"issue":"11","key":"10.1016\/j.thromres.2025.109540_bb0155","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1001\/jama.2024.1215","article-title":"Aspirin for metabolic dysfunction-associated steatotic liver disease without cirrhosis: a randomized clinical trial","volume":"331","author":"Simon","year":"2024","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.thromres.2025.109540_bb0160","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1152\/physrev.00044.2005","article-title":"The NOX family of ROS-generating NADPH oxidases: physiology and pathophysiology","volume":"87","author":"Bedard","year":"2007","journal-title":"Physiol. Rev."},{"issue":"1","key":"10.1016\/j.thromres.2025.109540_bb0165","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1038\/s41569-022-00737-2","article-title":"Gut-derived low-grade endotoxaemia, atherothrombosis and cardiovascular disease","volume":"20","author":"Violi","year":"2023","journal-title":"Nat. Rev. Cardiol."},{"issue":"1","key":"10.1016\/j.thromres.2025.109540_bb0170","article-title":"Nicotinamide adenine dinucleotide phosphate oxidases and metabolic dysfunction-associated steatotic liver disease","volume":"14","author":"Cammisotto","year":"2025","journal-title":"Antioxidants (Basel)"},{"issue":"5","key":"10.1016\/j.thromres.2025.109540_bb0175","first-page":"817","article-title":"Platelet NOX, a novel target for anti-thrombotic treatment","volume":"111","author":"Violi","year":"2014","journal-title":"Thromb. Haemost."},{"issue":"7","key":"10.1016\/j.thromres.2025.109540_bb0180","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1111\/bcp.13589","article-title":"Oleuropein, a component of extra virgin olive oil, lowers postprandial glycaemia in healthy subjects","volume":"84","author":"Carnevale","year":"2018","journal-title":"Br. J. Clin. Pharmacol."},{"issue":"3","key":"10.1016\/j.thromres.2025.109540_bb0185","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1016\/j.thromres.2011.12.002","article-title":"Platelet oxidative stress and thrombosis","volume":"129","author":"Violi","year":"2012","journal-title":"Thromb. Res."},{"issue":"10","key":"10.1016\/j.thromres.2025.109540_bb0190","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1016\/j.amjcard.2015.02.032","article-title":"Relation of nonalcoholic fatty liver disease and Framingham Risk Score to flow-mediated dilation in patients with cardiometabolic risk factors","volume":"115","author":"Pastori","year":"2015","journal-title":"Am. J. Cardiol."},{"issue":"18","key":"10.1016\/j.thromres.2025.109540_bb0195","doi-asserted-by":"crossref","DOI":"10.1172\/JCI186420","article-title":"MASH: the nexus of metabolism, inflammation, and fibrosis","volume":"135","author":"Steinberg","year":"2025","journal-title":"J. Clin. Invest."}],"container-title":["Thrombosis Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049384825002907?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049384825002907?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,1,10]],"date-time":"2026-01-10T02:26:11Z","timestamp":1768011971000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0049384825002907"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":39,"alternative-id":["S0049384825002907"],"URL":"https:\/\/doi.org\/10.1016\/j.thromres.2025.109540","relation":{},"ISSN":["0049-3848"],"issn-type":[{"value":"0049-3848","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Platelet Thromboxane B2 overproduction associated with liver fibrosis severity in patients with MASLD","name":"articletitle","label":"Article Title"},{"value":"Thrombosis Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.thromres.2025.109540","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"109540"}}